Results 41 to 50 of about 35,907 (256)

Endometrial Cancer and BRCA Mutations: A Systematic Review

Journal of Clinical Medicine, 2022
This systematic review identifies, evaluates, and summarises the findings of all relevant individual studies on the prevalence of BRCA mutation (BRCAm) in endometrial cancer patients and the incidence of endometrial cancer in BRCAm women patients. Consequently, the benefits and limits of a prophylactic hysterectomy at the time of the risk-reducing ...
Maria Gasparri, Serena Bellaminutti, Ammad Farooqi, Ilaria Cuccu, Violante Di Donato, Andrea Papadia   +5 more
openaire   +3 more sources

Detection of BRCA1, and BRCA2 Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting

Biomedicines, 2022
Background: Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for patients with metastatic castration-resistant prostate cancer harboring deleterious or suspected deleterious BRCA1 and/or 2 mutations.
Taylor Ryan McFarland, Vinay Mathew Thomas, Roberto Nussenzveig, Georges Gebrael, Nicolas Sayegh, Nishita Tripathi, Kamal Kant Sahu, Divyam Goel, Benjamin L. Maughan, Deepika Sirohi, Neeraj Agarwal, Umang Swami   +11 more
doaj   +1 more source

The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans

Hereditary Cancer in Clinical Practice, 2019
Background As a large-scale study of Koreans, we evaluated the association between BRCA mutation and the prevalence of non-breast and ovary cancers in first- and second-degree relatives of high-risk breast cancer patients.
Hakyoung Kim, Doo Ho Choi, Won Park, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jong Hwan Yu, Se Kyung Lee, Boo Yeon Jung   +11 more
doaj   +1 more source

Finding all BRCA pathogenic mutation carriers: best practice models [PDF]

, 2016
Identifying germline BRCA pathogenic mutations in patients with ovarian or breast cancer is a crucial component in the medical management of affected patients. Furthermore, the relatives of affected patients can be offered genetic testing.
Hoogerbrugge, N., Jongmans, M.C., Hoogerbrugge, Nicoline, Jongmans, Marjolijn CJ   +3 more
core   +1 more source

No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers

Breast Cancer Research and Treatment, 2007
Q2 ; Q1 ; Editorial ; 155-156 ; To the editorAbout 5% of breast cancers and 10% of ovariancancers are a result of germ line mutations in theBRCA1(MIM 113705) andBRCA2(MIM 600185)genes [1,2].
Muhammad U, Rashid, Diana, Torres, Anbreen, Zaidi, Farah, Rasheed, Faisal, Sultan, Abdul R, Shakoori, Asim, Amin, Ute, Hamann   +7 more
openaire   +3 more sources

BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers [PDF]

, 2017
Background: In breast cancer, BRCA promoter hypermethylation and BRCA germline mutations are said to occur together rarely, but this property has not yet been translated into a clinical test.
Cathy Beatrice Moelans, van Diest, Paul Joannes, Shoko Vos, Moelans, Cathy Beatrice, Paul Joannes van Diest, Vos, Shoko   +5 more
core   +1 more source

Evaluation of BRCAPRO risk assessment model in patients with ductal carcinoma in situ who underwent clinical BRCA genetic testing.

Frontiers in Genetics, 2016
The authors retrospectively aimed to determine which of the following 3 scenarios, related to DCIS entry into BRCAPRO, predicted BRCA mutation status more accurately: 1) DCIS as an invasive breast cancer (IBC) entered using the actual age of diagnosis, 2)
Nisreen eElsayegh, Angelica M. Gutierrez Barrera, Kimberly I. Muse, Heather eLin, Henry M Kuerer, Monica eHelm, Jennifer K. Litton, Banu K. Arun, Banu K. Arun   +8 more
doaj   +1 more source

Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families? [PDF]

PLoS ONE, 2018
Hereditary breast and ovarian cancer syndrome (HBOC) is most frequently caused by mutations in BRCA1 or BRCA2 (in short, BRCA) genes. The incidence of hereditary breast and ovarian cancer in relatives of BRCA mutation carriers who test negative for the ...
Rachel Mitchell, Lela Buckingham, Melody Cobleigh, Jacob Rotmensch, Kelly Burgess, Lydia Usha   +5 more
doaj   +1 more source

BRCA-EU mutation signature analysis.

, 2019
a SNV mutation signatures. SNVs are organized according to the SNV type (color). Within each type, SNVs are further organized into the pattern of flanking nucleotides (A—A, A—C, …,T—G, T—T). b SV mutation signatures.
Sohrab P. Shah (220828), Ali Bashashati (757758), Yi Kan Wang (445848), Tyler Funnell (6393164), Steven McKinney (61969), Allen W. Zhang (3817969), Diljot Grewal (6393167)   +6 more
core   +1 more source

BRCA Mutations and Breast Cancer Prevention [PDF]

Cancers, 2018
Women who inherit a deleterious BRCA1 or BRCA2 mutation face substantially increased risks of developing breast cancer, which is estimated at 70%. Although annual screening with magnetic resonance imaging (MRI) and mammography promotes the earlier detection of the disease, the gold standard for the primary prevention of breast cancer remains bilateral ...
openaire   +2 more sources